Self-Assembled Lipid Prodrug Nanomedicines for Cancerous and Noncancerous Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 241
Special Issue Editor
Interests: nanomedicine; drug delivery; tumor immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, there has been a growing trend in utilizing lipid-prodrug-based nanoassemblies (LPNs) for drug delivery, which have gained popularity due to their numerous advantages. A typical lipid prodrug encompasses a lipid carrier material, native drug, and a chemical spacer that possesses the potential to respond to stimuli. Through hydrophilic and hydrophobic interactions, lipid prodrugs spontaneously form supramolecular structures when introduced to aqueous environments. LPNs offer a combination of benefits derived from prodrugs and nanoparticles, facilitating drug release in response to stimuli while improving drug stability, bioavailability, and intracellular delivery.
The objective of this Special Issue of Pharmaceutics is to compile original research and review papers that focus on the development of lipid-prodrug-based nano-drug delivery systems for effectively treating severe diseases such as cancer, neurological disorders, infectious diseases, and uncontrolled inflammation.
Dr. Xiao Dong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lipid prodrug
- self-assembly
- nanomedicine
- drug delivery
- stimuli responsive
- drug release
- cancer
- non-cancerous disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
